Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jerry is KING! W. Gerald “Jerry” Newmin joined MultiCell as a director in June 1995. He currently serves as the Chairman, Chief Executive Officer, President, Chief Financial Officer and Secretary of MultiCell. Mr. Newmin served as Chief Executive Officer of MultiCell from June 1995 to May 2006, and was appointed to serve again as Chief Executive Officer on December 21, 2007. Mr. Newmin is Chairman, Chief Executive Officer, Secretary and a director of Xenogenics, a partially-owned subsidiary of MultiCell and Chief Executive Officer, Secretary and a director of MCTI, a partially-owned subsidiary of MultiCell. He has managed New York Stock Exchange and American Stock Exchange Fortune 500 companies. He was President of HealthAmerica Corporation, then the nation’s largest publicly-held HMO management company. He was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured. He was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive. He was instrumental in Whittaker’s entry into the U.S. and international health care markets. He was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States. He retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003. Mr. Newmin has a Bachelor’s degree in Accounting from Michigan State University. As our Chief Executive Officer, Mr. Newmin is specially qualified to serve on the Board because of his detailed knowledge of our operations and market.
You're right it does clearly indicate that. But at the same time it clearly states that the symbol is YIPI.PK. .PK is the universal suffix for Pink Sheets... Adding more to the confusion...
Just look at the qualifications for QX. YIPI doesn't even come close, so you will see my skepticism... http://www.otcmarkets.com/services/companies/otcqx-us/qualifications
OK! For future reference, it helps if you have some sort of facts to back up an opinion.
That is confusing to me too. I don't know why that is there. They are definitely not on the QX, and never were. Mods need to edit that...
Looking forward to it!
Fact case and point? Brother I showed the facts. If you suggest that not all of the numbers are there, that is not a fact, that is speculation, and neither of us can prove that one way or the other.
I'm just going off of the facts here. Interpret those facts however you wish!
Oh VNDM? If you assume that they heavily dilute the stock, then why do they only account for a mere 12% of all the volume in MCET for all of 2013? Compare that to ETRF (E*TRADE) which can account for 30% of all volume in 2013...
https://www.otcbb.com/asp/tradeact_mv.asp?SearchBy=issue&Issue=MCET&SortBy=volume&Month=12-1-2013&IMAGE1.x=12&IMAGE1.y=1
Oh VNDM? Aren't they on the ask at .0040?
I don't remember them being on the QX. The only way a non-reporting company can be on the QX is if they are published in the S&P or Mergent Manual for Blue Sky compliance. Any stock that can be defined as a penny stock is not allowed on the QX. In the case of YIPI, they don't even come close to the QX requirements. I've pasted them below the quote.
They do. OTCQX is the top tier. Companies like Adidas and Heineken are on the QX.
It was because on Sept 22, 2010 Rich filed a form 15 where they deregistered and stopped filing to the SEC. You have to be an SEC filer to be on the QB
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7470736
That kind of money doesn't come from little lemmings on iHub or from any scam newsletter. That kind of money was put into her for a reason I think. I agree with you completely.
"Follow the Money" as it were
I thought so too
MCT-485:
-Induction of tumor cell death upon direct exposure, while normal cells are minimally responsive to this agent.
-Production of TNF-alpha by cancer cells resulting in amplified tumor cell death and a localized immune reaction that has the potential to spread and curb progression of metastatic cancer.
There are other agents in development that are directly delivered to tumors with such a two-pronged mechanism of action: oncolytic viruses, plasmids encoding biological response modifiers, or TNF-alpha expressed by various vectors. MCT-485 offers an easy to manufacture, low cost alternative, with a potentially improved therapeutic index.
Primary liver cancer is the world’s fifth most frequently diagnosed cancer and is the second leading cause of cancer death.
Did you know MCET has a code of ethics?
http://www.multicelltech.com/wp-content/uploads/2013/11/code_of_ethics.pdf
More MCET DD
Cancer Stem Cells and Primary Liver Cancer
Tumor tissues are composed of a mixture of cells with some cancer cells exhibiting stem cell-like properties (cancer stem cells). Cancer stem cells are thought to play a role in a tumor’s resistance to therapy and mediate disease relapse, progression or metastasis. While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal.
Primary liver cancer, or hepatocellular carcinoma, begins in the cells of the liver itself, whereas metastatic liver cancer is cancer that begins in other parts of the body and spreads to the liver. According to the NCI, in 2008 there were approximately 21,400 new cases of primary liver cancer and intrahepatic bile duct cancer in the United States, and approximately 18,400 (86%) of those cases resulted in death in the first 18 months after diagnosis. Hepatocellular carcinoma, frequently accompanying Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.
The role liver stem cells play in the carcinogenic process of primary liver cancer has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies and thus, offer a unique opportunity to identify and develop a new generation of more effective anticancer agents (both small molecule therapeutics and biotherapies). MultiCell Technologies owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells. MultiCell is developing therapeutic product opportunities based on the concept of targeting cancer stem cells for the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer.
MCET has been littering PR wires with patent applications for sure, just look at al of them
Thank you, you too.
What pattern? Be specific
Thank you, sir! Much appreciated, I try hard! Hope I can help tame some of your justified skepticism
Yes. He was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States. He has been President of HealthAmerica Corporation, then the nation’s largest publicly-held HMO management company.
As our Chief Executive Officer, Mr. Newmin is specially qualified to serve on the Board of Directors because of his detailed knowledge of our operations and market.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204-13-054386.txt&FilePath=\2013\10\08\&CoName=MULTICELL+TECHNOLOGIES%2C+INC.&FormType=DEF+14A&RcvdDate=10%2F8%2F2013&pdf=
Let me highlight this point again.
I think you might be overestimating how many shares they have to sell...
Pursuant to the terms of the warrant and Debenture, LJCI may not acquire shares of our common stock to the extent such acquisition would cause LJCI to own more than 9.99% of our outstanding common stock immediately after such acquisition. Provided the aforementioned 9.99% cap is complied with, LJCI may in the future exercise or convert into, as applicable, a significant amount of additional shares of our common stock (e .g. as of August 31, 2013, there are a total of 4,659,629 shares remaining under the stock purchase warrant and a balance of $46,596 remaining on the Debenture, which is convertible pursuant to the formula set forth in the Debenture listed in the Exhibits section of this Annual Report on Form 10-K).
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204-13-054386.txt&FilePath=\2013\10\08\&CoName=MULTICELL+TECHNOLOGIES%2C+INC.&FormType=DEF+14A&RcvdDate=10%2F8%2F2013&pdf=
MCET DD:
Xenogenics Corporation (“Xenogenics”), a development-stage medical device company, is focused on the design of next-generation bioabsorbable stents for interventional cardiology and peripheral vascular applications. Xenogenics is a majority owned subsidiary of MultiCell Technologies, Inc. (OTCBB: MCET).
Xenogenics’ Ideal BioStent™ is the only stent incorporating salicylate, the active component in aspirin, directly into the polymer chain. As the polymer degrades, salicylate is released directly into the vessel wall, thereby providing anti-inflammatory and anti-thrombotic therapy aimed at reducing inflammation and the chance of blood clot formation while promoting blood vessel healing.
Xenogenics also incorporated Sirolimus (rapamycin) in addition to salicylate into the Ideal BioStent™ providing anti-restenotic therapy similar to today’s commonly used drug-eluting metal stents. Xenogenics’ bioabsorbable stent technology allows for the ability to layer different combinations of polymers and drugs, enabling the optimization of the delivery of combination drug therapies to provide superior clinical results. Xenogenics’ Ideal BioStent™ represents a significant advance over currently available stents, including:
The ability to promote positive vessel remodeling.
A significant reduction in late-stent thrombosis risk.
No metal artifact remaining in the patient’s body after vessel healing.
The reduced need for long-term and costly anti-platelet therapy.
MCET CEO DD:
W. Gerald “Jerry” Newmin joined the Company as a director in June 1995. He currently serves as the Chairman, Chief Executive Officer, President, Chief Financial Officer and Secretary. Mr. Newmin served as Chief Executive Officer of the Company from June 1995 to May 2006, and was appointed to serve again as Chief Executive Officer on December 21, 2007. Mr. Newmin is Chairman, Chief Executive Officer, Secretary and a director of Xenogenics, a partially-owned subsidiary of the Company, and Chief Executive Officer, Secretary and a director of MultiCell Immunotherapeutics, Inc., a partially-owned subsidiary of the Company. He has managed NYSE and American Stock Exchange Fortune 500 companies. He has been President of HealthAmerica Corporation, then the nation’s largest publicly-held HMO management company. He was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured. He was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive. He was instrumental in Whittaker’s entry into the US and international health care markets. He was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States. He retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003. Mr. Newmin has a Bachelor’s degree in Accounting from Michigan State University. As our Chief Executive Officer, Mr. Newmin is specially qualified to serve on the Board of Directors because of his detailed knowledge of our operations and market.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204-13-054386.txt&FilePath=\2013\10\08\&CoName=MULTICELL+TECHNOLOGIES%2C+INC.&FormType=DEF+14A&RcvdDate=10%2F8%2F2013&pdf=
Well put ospreyeye. Nearly 2B shares were scooped up on Thursday for a reason.
I imagine folks like you who have been here for so long are more than ready
Fibonacci is very interesting, I know about how the ratio appears in many places in nature. Don't get me wrong, your charting is great and I'm glad it has made you lots of money! My problem was just with the fib fans. They always were in different places and I could not understand why, and the reasoning behind the points you chose to use to create the fan.
On a side note, I grabbed 10,000 more shares of YIPI today, and I hope we slide toward those upper extensions!
Barely took a shove to do it
Yeah I've been hearing lots of talk about cavalry and claws.
Symbol changes have never seemed to be large catalysts as they don't give a reason for the company to be worth more IMO. I hope we hear from them soon.
If you are suggesting the ticker change will be the catalyst I disagree.
I've done nothing but state facts. I'm sorry your opinion is different.
I wish the best
Thanks..
Thank you! That is my whole point is that he is not a scam. I am not a "lemming", I notice how he alerts plays, and I agree that some of his plays can be found before he alerts. He has helped a lot of people make a lot of money regardless.
Yes I am aware. My point was, most of his picks are still above where he alerted.
Why do you say this. You're the one throwing around accusations. I'm just sharing facts.
Thanks..
I'm sure there was a fair share of losers as well. My point is, most of his calls have appreciated and maintained elevated valuations. I don't agree that he is a scam.
I'm aware. My post has nothing to do with this group. Nice calls, though.
True that.